English
简体中文
Total: £ 56.28
Published Date: 2026-04-08 | Pages: 128 | Tables: 121 | Service & Software
The global Gene Cell Therapy CDMO market was valued at US$ 2500 million in 2025 and is anticipated to reach US$ 4201 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Gene Cell Therapy CDMO provides end-to-end customized R&D and manufacturing services for advanced therapies such as gene therapy and cell therapy, from process development to production scale-up. Their core strength lies in addressing the extreme complexity of using live cells or viral vectors as "drugs," encompassing vector design and construction, cell collection and modification, process development and optimization, rigorous quality control and release testing, and clinical- and commercial-grade aseptic manufacturing. This field has extremely high barriers to entry, requiring companies to possess cutting-edge biological technologies, GMP-compliant closed-loop automated production systems, and the expertise to meet stringent global regulations. They are indispensable industrialization partners for pharmaceutical companies to bring cutting-edge therapies from the laboratory to market.
Gene Cell Therapy CDMO has a highly complex cost structure, primarily including cutting-edge R&D and highly skilled human resources costs, customized GMP facilities and expensive one-time production consumables, as well as stringent quality control and testing fees. Their gross profit margins range widely (typically 30%-60% or higher), depending mainly on the uniqueness of the technology platform, process efficiency, and capacity utilization. Early highly personalized therapies face significant cost pressures due to limited scale, while mature, large-scale platform-based manufacturing (such as allogeneic therapies and viral vectors) can achieve higher profitability through standardization and capacity expansion.
The global landscape of Gene Cell Therapy CDMO is characterized by "technology leadership, regional concentration, and multi-point breakthroughs." North America remains the absolute innovation center and largest source of demand globally, boasting the most mature capital markets, top biotech companies, and leading CDMO firms, dominating technology and standard development. Europe follows closely behind, possessing strong capabilities in specific technological routes and clinical translation thanks to its deep research foundation and rigorous regulatory system. The Asia-Pacific region, especially China, is becoming the fastest-growing market globally, driven by strong policy support, the rise of domestic innovative pharmaceutical companies, and huge clinical demand. It is rapidly moving from early technology imports to independent innovation and internationalization, with South Korea and Japan also actively expanding their presence. Currently, supply chain stability, geopolitical factors, and the need for proximity to clinical centers are driving the global production capacity layout towards regionalization and diversification.
This report delivers a comprehensive overview of the global Gene Cell Therapy CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gene Cell Therapy CDMO. The Gene Cell Therapy CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Gene Cell Therapy CDMO market comprehensively. Regional market sizes by Type, by Application, by Stage, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Gene Cell Therapy CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Catalent
Lonza
Charles River
Oxford Biomedica
Novartis
OBiO
GenScript
Pharmaron
Porton
Resilience
SK Pharmteco
Forge Biologics
Andelyn Biosciences
Roslin CT
eXmoor Pharma
Advanced Therapies
Catalent Biologics
Patheon Pharma Services
Segment by Type
Immune Cells
Stem Cell
Viral Vector
Plasmid DNA
Segment by Stage
Early-stage CDMO and preclinical CDMO
Clinical-stage CDMO
Commercial-stage CDMO
Segment by Production Mode
Centralized Factory Model
Distributed Regional Production Model
Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Stage, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Gene Cell Therapy CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Cell Therapy CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Immune Cells
1.2.3 Stem Cell
1.2.4 Viral Vector
1.2.5 Plasmid DNA
1.3 Market by Stage
1.3.1 Global Gene Cell Therapy CDMO Market Size Growth Rate by Stage: 2021 vs 2025 vs 2032
1.3.2 Early-stage CDMO and preclinical CDMO
1.3.3 Clinical-stage CDMO
1.3.4 Commercial-stage CDMO
1.4 Market by Production Mode
1.4.1 Global Gene Cell Therapy CDMO Market Size Growth Rate by Production Mode: 2021 vs 2025 vs 2032
1.4.2 Centralized Factory Model
1.4.3 Distributed Regional Production Model
1.5 Market by Application
1.5.1 Global Gene Cell Therapy CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical and Biotechnology Companies
1.5.3 Research and Academic Institutions
1.5.4 Hospital
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Gene Cell Therapy CDMO Market Perspective (2021–2032)
2.2 Global Gene Cell Therapy CDMO Growth Trends by Region
2.2.1 Global Gene Cell Therapy CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Gene Cell Therapy CDMO Historic Market Size by Region (2021–2026)
2.2.3 Gene Cell Therapy CDMO Forecasted Market Size by Region (2027–2032)
2.3 Gene Cell Therapy CDMO Market Dynamics
2.3.1 Gene Cell Therapy CDMO Industry Trends
2.3.2 Gene Cell Therapy CDMO Market Drivers
2.3.3 Gene Cell Therapy CDMO Market Challenges
2.3.4 Gene Cell Therapy CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Cell Therapy CDMO Players by Revenue
3.1.1 Global Top Gene Cell Therapy CDMO Players by Revenue (2021–2026)
3.1.2 Global Gene Cell Therapy CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Gene Cell Therapy CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Gene Cell Therapy CDMO Revenue
3.4 Global Gene Cell Therapy CDMO Market Concentration Ratio
3.4.1 Global Gene Cell Therapy CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Cell Therapy CDMO Revenue in 2025
3.5 Global Key Players of Gene Cell Therapy CDMO Head Offices and Areas Served
3.6 Global Key Players of Gene Cell Therapy CDMO, Products and Applications
3.7 Global Key Players of Gene Cell Therapy CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Gene Cell Therapy CDMO Breakdown Data by Type
4.1 Global Gene Cell Therapy CDMO Historic Market Size by Type (2021–2026)
4.2 Global Gene Cell Therapy CDMO Forecasted Market Size by Type (2027–2032)
5 Gene Cell Therapy CDMO Breakdown Data by Application
5.1 Global Gene Cell Therapy CDMO Historic Market Size by Application (2021–2026)
5.2 Global Gene Cell Therapy CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Gene Cell Therapy CDMO Market Size (2021–2032)
6.2 North America Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Gene Cell Therapy CDMO Market Size by Country (2021–2026)
6.4 North America Gene Cell Therapy CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Cell Therapy CDMO Market Size (2021–2032)
7.2 Europe Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Gene Cell Therapy CDMO Market Size by Country (2021–2026)
7.4 Europe Gene Cell Therapy CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Gene Cell Therapy CDMO Market Size (2021–2032)
8.2 Asia-Pacific Gene Cell Therapy CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Gene Cell Therapy CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Gene Cell Therapy CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Gene Cell Therapy CDMO Market Size (2021–2032)
9.2 Latin America Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Gene Cell Therapy CDMO Market Size by Country (2021–2026)
9.4 Latin America Gene Cell Therapy CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Cell Therapy CDMO Market Size (2021–2032)
10.2 Middle East & Africa Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Catalent
11.1.1 Catalent Company Details
11.1.2 Catalent Business Overview
11.1.3 Catalent Gene Cell Therapy CDMO Introduction
11.1.4 Catalent Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.1.5 Catalent Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Gene Cell Therapy CDMO Introduction
11.2.4 Lonza Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.2.5 Lonza Recent Development
11.3 Charles River
11.3.1 Charles River Company Details
11.3.2 Charles River Business Overview
11.3.3 Charles River Gene Cell Therapy CDMO Introduction
11.3.4 Charles River Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.3.5 Charles River Recent Development
11.4 Oxford Biomedica
11.4.1 Oxford Biomedica Company Details
11.4.2 Oxford Biomedica Business Overview
11.4.3 Oxford Biomedica Gene Cell Therapy CDMO Introduction
11.4.4 Oxford Biomedica Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.4.5 Oxford Biomedica Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Gene Cell Therapy CDMO Introduction
11.5.4 Novartis Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.5.5 Novartis Recent Development
11.6 OBiO
11.6.1 OBiO Company Details
11.6.2 OBiO Business Overview
11.6.3 OBiO Gene Cell Therapy CDMO Introduction
11.6.4 OBiO Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.6.5 OBiO Recent Development
11.7 GenScript
11.7.1 GenScript Company Details
11.7.2 GenScript Business Overview
11.7.3 GenScript Gene Cell Therapy CDMO Introduction
11.7.4 GenScript Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.7.5 GenScript Recent Development
11.8 Pharmaron
11.8.1 Pharmaron Company Details
11.8.2 Pharmaron Business Overview
11.8.3 Pharmaron Gene Cell Therapy CDMO Introduction
11.8.4 Pharmaron Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.8.5 Pharmaron Recent Development
11.9 Porton
11.9.1 Porton Company Details
11.9.2 Porton Business Overview
11.9.3 Porton Gene Cell Therapy CDMO Introduction
11.9.4 Porton Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.9.5 Porton Recent Development
11.10 Resilience
11.10.1 Resilience Company Details
11.10.2 Resilience Business Overview
11.10.3 Resilience Gene Cell Therapy CDMO Introduction
11.10.4 Resilience Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.10.5 Resilience Recent Development
11.11 SK Pharmteco
11.11.1 SK Pharmteco Company Details
11.11.2 SK Pharmteco Business Overview
11.11.3 SK Pharmteco Gene Cell Therapy CDMO Introduction
11.11.4 SK Pharmteco Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.11.5 SK Pharmteco Recent Development
11.12 Forge Biologics
11.12.1 Forge Biologics Company Details
11.12.2 Forge Biologics Business Overview
11.12.3 Forge Biologics Gene Cell Therapy CDMO Introduction
11.12.4 Forge Biologics Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.12.5 Forge Biologics Recent Development
11.13 Andelyn Biosciences
11.13.1 Andelyn Biosciences Company Details
11.13.2 Andelyn Biosciences Business Overview
11.13.3 Andelyn Biosciences Gene Cell Therapy CDMO Introduction
11.13.4 Andelyn Biosciences Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.13.5 Andelyn Biosciences Recent Development
11.14 Roslin CT
11.14.1 Roslin CT Company Details
11.14.2 Roslin CT Business Overview
11.14.3 Roslin CT Gene Cell Therapy CDMO Introduction
11.14.4 Roslin CT Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.14.5 Roslin CT Recent Development
11.15 eXmoor Pharma
11.15.1 eXmoor Pharma Company Details
11.15.2 eXmoor Pharma Business Overview
11.15.3 eXmoor Pharma Gene Cell Therapy CDMO Introduction
11.15.4 eXmoor Pharma Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.15.5 eXmoor Pharma Recent Development
11.16 Advanced Therapies
11.16.1 Advanced Therapies Company Details
11.16.2 Advanced Therapies Business Overview
11.16.3 Advanced Therapies Gene Cell Therapy CDMO Introduction
11.16.4 Advanced Therapies Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.16.5 Advanced Therapies Recent Development
11.17 Catalent Biologics
11.17.1 Catalent Biologics Company Details
11.17.2 Catalent Biologics Business Overview
11.17.3 Catalent Biologics Gene Cell Therapy CDMO Introduction
11.17.4 Catalent Biologics Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.17.5 Catalent Biologics Recent Development
11.18 Patheon Pharma Services
11.18.1 Patheon Pharma Services Company Details
11.18.2 Patheon Pharma Services Business Overview
11.18.3 Patheon Pharma Services Gene Cell Therapy CDMO Introduction
11.18.4 Patheon Pharma Services Revenue in Gene Cell Therapy CDMO Business (2021–2026)
11.18.5 Patheon Pharma Services Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Immune Cells
Table 3. Key Players of Stem Cell
Table 4. Key Players of Viral Vector
Table 5. Key Players of Plasmid DNA
Table 6. Global Gene Cell Therapy CDMO Market Size Growth Rate by Stage (US$ Million): 2021 vs 2025 vs 2032
Table 7. Key Players of Early-stage CDMO and preclinical CDMO
Table 8. Key Players of Clinical-stage CDMO
Table 9. Key Players of Commercial-stage CDMO
Table 10. Global Gene Cell Therapy CDMO Market Size Growth Rate by Production Mode (US$ Million): 2021 vs 2025 vs 2032
Table 11. Key Players of Centralized Factory Model
Table 12. Key Players of Distributed Regional Production Model
Table 13. Global Gene Cell Therapy CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 14. Global Gene Cell Therapy CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 15. Global Gene Cell Therapy CDMO Market Size by Region (US$ Million), 2021–2026
Table 16. Global Gene Cell Therapy CDMO Market Share by Region (2021–2026)
Table 17. Global Gene Cell Therapy CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 18. Global Gene Cell Therapy CDMO Market Share by Region (2027–2032)
Table 19. Gene Cell Therapy CDMO Market Trends
Table 20. Gene Cell Therapy CDMO Market Drivers
Table 21. Gene Cell Therapy CDMO Market Challenges
Table 22. Gene Cell Therapy CDMO Market Restraints
Table 23. Global Gene Cell Therapy CDMO Revenue by Players (US$ Million), 2021–2026
Table 24. Global Gene Cell Therapy CDMO Market Share by Players (2021–2026)
Table 25. Global Top Gene Cell Therapy CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Gene Cell Therapy CDMO Revenue, 2025
Table 26. Ranking of Global Top Gene Cell Therapy CDMO Companies by Revenue (US$ Million) in 2025
Table 27. Global 5 Largest Players Market Share by Gene Cell Therapy CDMO Revenue (CR5 and HHI), 2021–2026
Table 28. Global Key Players of Gene Cell Therapy CDMO, Headquarters and Area Served
Table 29. Global Key Players of Gene Cell Therapy CDMO, Products and Applications
Table 30. Global Key Players of Gene Cell Therapy CDMO, Date of General Availability (GA)
Table 31. Mergers and Acquisitions, Expansion Plans
Table 32. Global Gene Cell Therapy CDMO Market Size by Type (US$ Million), 2021–2026
Table 33. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2021–2026)
Table 34. Global Gene Cell Therapy CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 35. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2027–2032)
Table 36. Global Gene Cell Therapy CDMO Market Size by Application (US$ Million), 2021–2026
Table 37. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2021–2026)
Table 38. Global Gene Cell Therapy CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 39. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2027–2032)
Table 40. North America Gene Cell Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. North America Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 42. North America Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 43. Europe Gene Cell Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Europe Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 45. Europe Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 46. Asia-Pacific Gene Cell Therapy CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 47. Asia-Pacific Gene Cell Therapy CDMO Market Size by Region (US$ Million), 2021–2026
Table 48. Asia-Pacific Gene Cell Therapy CDMO Market Size by Region (US$ Million), 2027–2032
Table 49. Latin America Gene Cell Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 50. Latin America Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 51. Latin America Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 52. Middle East & Africa Gene Cell Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 53. Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 54. Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 55. Catalent Company Details
Table 56. Catalent Business Overview
Table 57. Catalent Gene Cell Therapy CDMO Product
Table 58. Catalent Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 59. Catalent Recent Development
Table 60. Lonza Company Details
Table 61. Lonza Business Overview
Table 62. Lonza Gene Cell Therapy CDMO Product
Table 63. Lonza Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 64. Lonza Recent Development
Table 65. Charles River Company Details
Table 66. Charles River Business Overview
Table 67. Charles River Gene Cell Therapy CDMO Product
Table 68. Charles River Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 69. Charles River Recent Development
Table 70. Oxford Biomedica Company Details
Table 71. Oxford Biomedica Business Overview
Table 72. Oxford Biomedica Gene Cell Therapy CDMO Product
Table 73. Oxford Biomedica Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 74. Oxford Biomedica Recent Development
Table 75. Novartis Company Details
Table 76. Novartis Business Overview
Table 77. Novartis Gene Cell Therapy CDMO Product
Table 78. Novartis Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 79. Novartis Recent Development
Table 80. OBiO Company Details
Table 81. OBiO Business Overview
Table 82. OBiO Gene Cell Therapy CDMO Product
Table 83. OBiO Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 84. OBiO Recent Development
Table 85. GenScript Company Details
Table 86. GenScript Business Overview
Table 87. GenScript Gene Cell Therapy CDMO Product
Table 88. GenScript Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 89. GenScript Recent Development
Table 90. Pharmaron Company Details
Table 91. Pharmaron Business Overview
Table 92. Pharmaron Gene Cell Therapy CDMO Product
Table 93. Pharmaron Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 94. Pharmaron Recent Development
Table 95. Porton Company Details
Table 96. Porton Business Overview
Table 97. Porton Gene Cell Therapy CDMO Product
Table 98. Porton Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 99. Porton Recent Development
Table 100. Resilience Company Details
Table 101. Resilience Business Overview
Table 102. Resilience Gene Cell Therapy CDMO Product
Table 103. Resilience Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 104. Resilience Recent Development
Table 105. SK Pharmteco Company Details
Table 106. SK Pharmteco Business Overview
Table 107. SK Pharmteco Gene Cell Therapy CDMO Product
Table 108. SK Pharmteco Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 109. SK Pharmteco Recent Development
Table 110. Forge Biologics Company Details
Table 111. Forge Biologics Business Overview
Table 112. Forge Biologics Gene Cell Therapy CDMO Product
Table 113. Forge Biologics Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 114. Forge Biologics Recent Development
Table 115. Andelyn Biosciences Company Details
Table 116. Andelyn Biosciences Business Overview
Table 117. Andelyn Biosciences Gene Cell Therapy CDMO Product
Table 118. Andelyn Biosciences Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 119. Andelyn Biosciences Recent Development
Table 120. Roslin CT Company Details
Table 121. Roslin CT Business Overview
Table 122. Roslin CT Gene Cell Therapy CDMO Product
Table 123. Roslin CT Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 124. Roslin CT Recent Development
Table 125. eXmoor Pharma Company Details
Table 126. eXmoor Pharma Business Overview
Table 127. eXmoor Pharma Gene Cell Therapy CDMO Product
Table 128. eXmoor Pharma Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 129. eXmoor Pharma Recent Development
Table 130. Advanced Therapies Company Details
Table 131. Advanced Therapies Business Overview
Table 132. Advanced Therapies Gene Cell Therapy CDMO Product
Table 133. Advanced Therapies Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 134. Advanced Therapies Recent Development
Table 135. Catalent Biologics Company Details
Table 136. Catalent Biologics Business Overview
Table 137. Catalent Biologics Gene Cell Therapy CDMO Product
Table 138. Catalent Biologics Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 139. Catalent Biologics Recent Development
Table 140. Patheon Pharma Services Company Details
Table 141. Patheon Pharma Services Business Overview
Table 142. Patheon Pharma Services Gene Cell Therapy CDMO Product
Table 143. Patheon Pharma Services Revenue in Gene Cell Therapy CDMO Business (US$ Million), 2021–2026
Table 144. Patheon Pharma Services Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
Table 148. Authors List of This Report
List of Figures
Figure 1. Gene Cell Therapy CDMO Picture
Figure 2. Global Gene Cell Therapy CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Gene Cell Therapy CDMO Market Share by Type: 2025 vs 2032
Figure 4. Immune Cells Features
Figure 5. Stem Cell Features
Figure 6. Viral Vector Features
Figure 7. Plasmid DNA Features
Figure 8. Global Gene Cell Therapy CDMO Market Size Comparison by Stage (US$ Million), 2021–2032
Figure 9. Early-stage CDMO and preclinical CDMO Features
Figure 10. Clinical-stage CDMO Features
Figure 11. Commercial-stage CDMO Features
Figure 12. Global Gene Cell Therapy CDMO Market Size Comparison by Production Mode (US$ Million), 2021–2032
Figure 13. Centralized Factory Model Features
Figure 14. Distributed Regional Production Model Features
Figure 15. Global Gene Cell Therapy CDMO Market Size by Application (US$ Million), 2021–2032
Figure 16. Global Gene Cell Therapy CDMO Market Share by Application: 2025 vs 2032
Figure 17. Pharmaceutical and Biotechnology Companies Case Studies
Figure 18. Research and Academic Institutions Case Studies
Figure 19. Hospital Case Studies
Figure 20. Others Case Studies
Figure 21. Gene Cell Therapy CDMO Report Years Considered
Figure 22. Global Gene Cell Therapy CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 23. Global Gene Cell Therapy CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Gene Cell Therapy CDMO Market Share by Region: 2025 vs 2032
Figure 25. Global Gene Cell Therapy CDMO Market Share by Players in 2025
Figure 26. Global Gene Cell Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Gene Cell Therapy CDMO Revenue in 2025
Figure 28. North America Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. North America Gene Cell Therapy CDMO Market Share by Country (2021–2032)
Figure 30. United States Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Canada Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Europe Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Europe Gene Cell Therapy CDMO Market Share by Country (2021–2032)
Figure 34. Germany Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. France Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. U.K. Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Italy Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Russia Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Ireland Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Asia-Pacific Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Asia-Pacific Gene Cell Therapy CDMO Market Share by Region (2021–2032)
Figure 42. China Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Japan Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. South Korea Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Southeast Asia Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. India Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Australia & New Zealand Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Latin America Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Latin America Gene Cell Therapy CDMO Market Share by Country (2021–2032)
Figure 50. Mexico Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Brazil Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 52. Middle East & Africa Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Middle East & Africa Gene Cell Therapy CDMO Market Share by Country (2021–2032)
Figure 54. Israel Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. Saudi Arabia Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 56. UAE Gene Cell Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. Catalent Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 58. Lonza Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 59. Charles River Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 60. Oxford Biomedica Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 61. Novartis Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 62. OBiO Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 63. GenScript Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 64. Pharmaron Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 65. Porton Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 66. Resilience Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 67. SK Pharmteco Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 68. Forge Biologics Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 69. Andelyn Biosciences Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 70. Roslin CT Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 71. eXmoor Pharma Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 72. Advanced Therapies Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 73. Catalent Biologics Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 74. Patheon Pharma Services Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021–2026)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
